Parameter
| Biomarker | miR-132 | Full name | MicroRNA-132 | Molecular Type | Nucleic acid (RNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | ~22 nt (~6.6 kDa) | Core Functional Dimensions | Prognostic assessment and therapeutic targets | |
| Disease | Heart failure | Disease Subtypes | / | ||
| Organ | Myocardium, neurons | Test Sample / Technology Platform | Plasma (RT-qPCR, small RNA sequencing) | ||
| Pathobiological Mechanisms | Myocardial cells are up-regulated during stress and promote myocardial hypertrophy and remodeling by inhibiting SIRT1. Digoxin could further up-regulate the expression of SIRT1 | ||||
| Clinical Availability Status | Cutting-edge research/clinical trials: - HF-REVERT test (Ⅱ) evaluation (DR132L) the curative effect of miR-132 drug resistance; -A >5-fold increase in miR-132 in acute HF suggested a HR of 2.9 for 1-year mortality | ||||
| Notes and Dynamics | DR132L, a miR-132 antagonist, improved LVEF by 5.2% in patients with HFrEF in phase Ib trial. MiR-132 and myocardial fibrosis markers (PIIINP) positive correlation (r = 0.62), and can be used as anti fibrosis treatment the curative effect of monitoring indicators; The ischemic miR-132 HF patients were significantly higher than that of ischemic HF, can assist the cause identification | ||||